Chronic Constipation Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Chronic Constipation Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major chronic constipation markets are expected to exhibit a CAGR of 4.64% during 2024-2034.

The chronic constipation market has been comprehensively analyzed in IMARC's new report titled "Chronic Constipation Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic constipation refers to a medical condition characterized by long-term difficulty in passing stools and infrequent bowel movements. It is diagnosed when these indications persist for several weeks or longer. Individuals suffering from chronic constipation may experience various symptoms, such as having less than three bowel movements per week, straining during bowel movements, passing hard or lumpy stools, feeling of incomplete evacuation, abdominal discomfort or bloating, need for manual maneuvers to aid in the passage of stools, etc. The diagnosis involves a comprehensive evaluation of the patient's medical history, a physical examination, and the assessment of specific criteria. Healthcare professionals may inquire about the frequency and consistency of bowel movements, the presence of associated symptoms, dietary and lifestyle habits, and any underlying medical conditions or medications. They may perform a physical examination to check for signs of abdominal discomfort or abnormality. Additionally, numerous diagnostic procedures, such as blood tests to assess thyroid function or rule out underlying conditions, imaging studies to evaluate the colon or rectum, and several tests to determine the function of the pelvic floor muscles, may be suggested based on the patient's specific symptoms and clinical presentation.

The increasing cases of structural abnormalities in the colon or rectum, including rectal prolapse, anal fissures, colorectal strictures, etc., that can obstruct the normal flow of stool are primarily driving the chronic constipation market. Furthermore, the rising prevalence of several associated risk factors, such as inadequate fluid and fiber intake, lack of physical activity, hormonal imbalances, intestinal disorders, advancing age, etc., is creating a positive outlook for the market. In addition to this, the widespread adoption of over-the-counter laxatives, including bulk-forming laxatives, osmotic laxatives, stimulant laxatives, stool softeners, etc., for stimulating bowel movements and improving gut motility is also bolstering the market growth. Moreover, the emerging popularity of biofeedback therapy, which involves using sensors to provide feedback on muscle activity and instruct patients on how to control and strengthen their pelvic floor muscles to enhance the coordination and efficiency of bowel movements, is further acting as another significant growth-inducing factor. Additionally, the escalating utilization of transcutaneous electrical nerve stimulation (TENS) therapy, since it aids in stimulating nerve pathways and enhancing colonic motility, is expected to drive the chronic constipation market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the chronic constipation market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for chronic constipation and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic constipation market in any manner.

Recent Developments:
In July 2023, researchers at the Alzheimer's Association International Conference (AAIC) reported the worsening of cognition among chronically constipated individuals. They also stated that bowel movement frequency of every three days or less was linked with 73% higher odds of subjective cognitive decline.
In June 2023, Ironwood Pharmaceuticals, Inc. announced that the U.S. FDA had approved Linzess (linaclotide) as a once-daily drug to treat chronic constipation in pediatric patients aged 6-17 years. Linzess is the first and only FDA-approved prescription medication for chronic constipation in this patient population.
In May 2023, Vibrant Gastro delivered an abstract at the 2023 Digestive Disease Week Conference in Chicago. Vibrant uses moderate vibrations to mechanically stimulate the colon, causing it to constrict and efficiently propel its contents. Vibrant's timed stimulation is designed to give vibrations that help the colon contract mechanically in accordance with the body's natural circadian rhythm.

Key Highlights:
Chronic constipation affects approximately 15% of adults, ranking as the sixth most frequent gastrointestinal ailment.
The prevalence of chronic constipation is greater among older adults on account of age-related factors, such as lack of exercise, fiber-deficient diets, and the use of certain constipating drugs to treat various other medical conditions.
In the United States, chronic constipation accounts for around 1 million hospital visits each year.
Females are more commonly affected by chronic constipation than males. The female-to-male ratio is approximately 2.2:1.
In the general population, the prevalence of constipation in urban areas was 6.7%, which was much lower than in rural areas, where the prevalence rate was 7.2%.

Drugs:
Linzess refers to a first-in-class guanylate cyclase-C (GC-C) agonist, which is developed and marketed by Ironwood and AbbVie in the United States. It acts locally in the intestine without significant systemic exposure. The drug has been available since 2012 for the management of adults with irritable bowel syndrome with constipation or chronic idiopathic constipation.

Motegrity is a once-daily, selective serotonin-4 (5-HT4) receptor agonist drug used in adults to treat chronic idiopathic constipation. The therapeutic candidate works by enhancing colonic peristalsis to boost bowel motility. Motegrity is available as a tablet for oral consumption.

Pizensy (lactitol) is a simple monosaccharide sugar alcohol treatment for chronic idiopathic constipation in adults. Pizensy is available as an off-white crystalline powder for oral use. The indicated daily dose is 20 grams (combined with 4 to 8 ounces of water, tea, juice, coffee, or soda), ideally with meals. It acts by exerting an osmotic impact, which causes water to enter the small intestine, resulting in a laxative action in the colon.


Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the chronic constipation market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the chronic constipation market
Reimbursement scenario in the market
In-market and pipeline drugs

Competitive Landscape:
This report also provides a detailed analysis of the current chronic constipation marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.


Key Questions Answered in this Report:
Market Insights

How has the chronic constipation market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the chronic constipation market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the chronic constipation market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of chronic constipation across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic constipation by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic constipation by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with chronic constipation across the seven major markets?
What is the size of the chronic constipation patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of chronic constipation?
What will be the growth rate of patients across the seven major markets?

Chronic Constipation: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for chronic constipation drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic constipation market?
What are the key regulatory events related to the chronic constipation market?
What is the structure of clinical trial landscape by status related to the chronic constipation market?
What is the structure of clinical trial landscape by phase related to the chronic constipation market?
What is the structure of clinical trial landscape by route of administration related to the chronic constipation market?